Osteoprotegerin Human ELISA

Summary

Osteoprotegerin (OPG) or osteoclastogenesis inhibitory factor (OCIF) is a secretory glycoprotein belonging to TNF receptor superfamily. OPG consists of 401 amino acid residues, it has a molecular weight of 60 kDa as a monomer and 120 kDa as a disulfide-linked dimer and is produced in different tissues, e.g. bone, skin, liver, stomach, intestine and lung. Osteoprotegerin inhibits the recruitment, proliferation and activation of osteoclasts. Osteoclast formation activity may be monitored principally by determination of concentration ratio of osteoprotegerin ligand (OPGL)/OPG. Alteration of this ratio may be the cause of bone loss in many imbalances in bone metabolism such as osteoporosis, osteopetrosis, hypercalcemia, metastatic osteolytic lesions and rheumatic bone degradation.

Features

• European Union: for in vitro diagnostic use
• Rest of the world: for research use only!
• The total assay time is less than 3.5 hours
• The kit measures osteoprotegerin in serum and plasma (EDTA, citrate, heparin)
• Assay format is 96 wells
• Quality Controls are human serum based
• Standard is recombinant protein based
• Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Bone and cartilage metabolism

Assay format

Sandwich ELISA, Biotin-labelled antibody

Applications

Plasma-Citrate, Plasma-EDTA, Plasma-Heparin, Serum

Sample requirements

35 µl/well

Storage/Shipping

Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration range

1.5 – 60 pmol/l

Limit of detection

0.10 pmol/l

Intra-assay (Within-Run, n=8)

CV = 3.5 %

Inter-assay (Run-to-Run, n=3)

CV = 5.8 %

Spiking Recovery

106.7 %

Dilution Linearity

107.6 %

Cross-Reactivity

References to this product

• Abd El Dayem S M, Anwar G M, Salama H, Kamel A F, Emara N. Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children with congenital adrenal, hyperplasia. Arch Med Sci. 2010 Jan;:104-110
• Abdel-Hameed RE, Badr HW, Abdallah AA, Hanna WM, Salah N. Osteoporosis in diabetic children. Journal of American Science. 2010;6(12)
• Avbersek-Luznik I, Balon BP, Rus I, Marc J. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?. Nephrol Dial Transplant. 2005 Mar;20 (3):566-70
• Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care. 2005 Sep;28 (9):2176-80
• Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonne JF, Cristol JP, Dupuy AM. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007 Nov;30 (11):2934-9
• Barbagallo I, Vanella A, Peterson SJ, Kim DH, Tibullo D, Giallongo C, Vanella L, Parrinello N, Palumbo GA, Di Raimondo F, Abraham NG, Asprinio D. Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation. J Bone Miner Metab. 2010 May;28 (3):276-88
• Bargnoux AS, Dupuy AM, Garrigue V, Deleuze S, Cristol JP, Mourad G. Renal transplantation decreases osteoprotegerin levels. Transplant Proc. 2006 Sep;38 (7):2317-8
• Cao JJ, Johnson LK, Hunt JR. A Diet High in Meat Protein and Potential Renal Acid Load Increases Fractional Calcium Absorption and Urinary Calcium Excretion without Affecting Markers of Bone Resorption or Formation in Postmenopausal Women. J Nutr. 2011 Mar;141 (3):391-7
• Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT. Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol. 2010 Oct;29 (10):1155-61
• Clancy P, Oliver L, Jayalath R, Buttner P, Golledge J. Assessment of a serum assay for quantification of abdominal aortic calcification. Arterioscler Thromb Vasc Biol . Nov;26(11):2574-6 (2006)
• Dai SM, Nishioka K, Yudoh K. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. Ann Rheum Dis. 2004 Nov;63 (11):1379-86
• Dimitrow PP, Jawień M, Gackowski A. The Influence of Statins on Levels of Calcification Biomarkers in Patients with Aortic Sclerosis or Mild Aortic Stenosis. J Heart Valve Dis. January 2011;20 (1)
• Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease. Ther Apher Dial. 2009 Feb;13 (1):49-55
• Dundar U, Kavuncu V, Ciftci IH, Evcik D, Solak O, Cakir T. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. J Bone Miner Metab. 2009;27 (4):464-70
• ElBaky AA, Ismail N, Salama E, Abou-Zekri M, Fatouh A, Ragab S. Inappropriate restriction of dietary gluten and associated bone acquisition and bone density in Egyptian children with coeliac disease. Arch Med Sci. 2009; 5, 4;:589-595
• Esen H, Büyükyazı G, Ulman C, Taneli F, Arı Z, Gözlükaya F, Tıkız H. Do Walking Programs Affect C-Reactive Protein, Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-Kappaβ Ligand?. Turkish Journal of Biochemistr. 2009; 34 (3) ; 178–186.;
• Ford ML, Smith ER, Tomlinson LA, Chatterjee PK, Rajkumar C, Holt SG. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol Dial Transplant. 2011 Jul 12;
• Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Santolaria-Fernandez F, De la Vega-Prieto MJ, Milena-Abril A, Sanchez-Perez MJ, Martinez-Riera A, Gomez-Rodriguez Mde L. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol. 2006 May-Jun;41 (3):261-6
• Gogo PB Jr, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL. Osteoprotegerin is not associated with angiographic coronary calcification. J Thromb Thrombolysis. 2006 Dec;22 (3):177-83
• Golledge J, Jayalath R, Oliver L, Parr A, Schurgers L, Clancy P. Relationship between CT anthropometric measurements, adipokines and abdominal aortic calcification. Atherosclerosis. 2008 Mar;197 (1):428-34
• Gonzalez-Reimers E, Alvisa-Negrin J, Santolaria-Fernandez F, Ros-Vilamajo R, Martin-Gonzalez MC, Hernandez-Betancor I, Garcia-Valdecasas-Campelo E, Gonzalez-Diaz A. Prognosis of osteopenia in chronic alcoholics. Alcohol. 2010 Nov 3;
• Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, Arikan E, Tugrul A. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res. 2007;120 (4):511-6
• Gurban C,Zosin I, Sfrijan F, Cojocaru M, Vermesan H, Vermesan D, Savescu I, Radulov I, Drugarin D, Erdelean V. The OPG/sRANKL Systems and the low bone mineral density in postmenopausal osteoporosis. Acta Endocrinologica. vol. V, no. 1, p. 27-40, 2009;
• Gurban CV, Drugarin D, Corneanu M, Glaja R, Faur A, Ciacli C. The RANK/sRANKL/OPG System - Marker of bone cells in postmenopausal Osteoporosis. Journal of Experimental Medica. Year XIV · Nr.4/2007 · Pag. 17;
• Ismail NA, El-Shabrawi M, Fatouh AA, Salama E, Abd El Baky AM, El Ghoroury EA, Thabet EH. Risk of Osteoporosis in children with chronic liver diseases. International Journal of Acade. September, 2010;2 (5)
• Kandil ME, Mourad A, Hamshary AE, Hussein G, Ahmed A. Evaluation of bone mineral density and bone turnover markers in Egyptian children with juvenile rheumatoid arthritis. Arch Med Sci. 2009; 5, 3: 434-442;
• Kanzaki H, Chiba M, Sato A, Miyagawa A, Arai K, Nukatsuka S, Mitani H. Cyclical tensile force on periodontal ligament cells inhibits osteoclastogenesis through OPG induction. J Dent Res. 2006 May;85 (5):457-62
• Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf). 2005 Nov;63 (5):594-8
• Kolahi S, Ghorbanihaghjo A, Alizadeh S, Rashtchizadeh N, Argani H, Khabazzi AR, Hajialilo M, Bahreini E. Fish oil supplementation decreases serum soluble receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in female patients with rheumatoid arthritis. Clin Biochem. 2009 Dec 21;
• Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK, Pangalis GA. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur J Haematol. 2004 Apr;72 (4):252-8
• Maimoun L, Couret I, Mariano-Goulart D, Dupuy AM, Micallef JP, Peruchon E, Ohanna F, Cristol JP, Rossi M, Leroux JL. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. Calcif Tissue Int. 2005 Jun;76 (6):404-11
• Marchelli D, Piodi LP, Corradini C, Parravicini L, Verdoia C, Ulivieri FM. Increased serum OPG in atrophic nonunion shaft fractures. J Orthop Traumatol. 2009 Jun;10 (2):55-8
• Mencej-Bedrac S, Prezelj J, Kocjan T, Teskac K, Ostanek B, Smelcer M, Marc J. The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumour necrosis factor superfamily member 11 genes are associated with bone mineral density. J Mol Endocrinol. 2009 Mar;42 (3):239-47
• Mora S, Zamproni I, Cafarelli L, Giacomet V, Erba P, Zuccotti G, Vigano A. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. AIDS. 2007 May 31;21 (9):1129-35
• Morena M, Bosc JY, Jaussent I, Dupuy AM, Terrier N, Leray-Moragues H, Flavier JL, Maurice F, Delcourt C, Cristol JP, Canaud B. The role of mineral metabolism and inflammation on dialysis vascular access failure. J Vasc Access. 2006 Apr-Jun;7 (2):77-82
• Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, Maurice F, Delcourt C, Cristol JP, Canaud B, Dupuy AM. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006 Jan;17 (1):262-70
• Naylor KE, Rogers A, Fraser RB, Hall V, Eastell R, Blumsohn A. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab. 2003 Nov;88 (11):5361-5
• Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol. 2008 Nov;159 (5):603-8
• Ochiai M, Nakashima A, Takasugi N, Kiribayashi K, Kawai T, Usui K, Shigemoto K, Hamaguchi N, Kohno N, Yorioka N. Vitamin K alters bone metabolism markers in hemodialysis patients with a low serum parathyroid hormone level. Nephron Clin Pract. 2011;117 (1):c15-9
• Ozkaya O, Buyan N, Bideci A, Gonen S, Ortac E, Fidan K, Cinaz P, Soylemezoglu O. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis. Nephron Clin Pract. 2007;105 (4):c153-8
• Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005 Nov;90 (11):6323-31
• Salama HM, El-Dayem SA, Yousef H, Fawzy A, Abou-Ismail L, El-lebedy D. The effects of L-thyroxin replacement therapy on bone minerals and body composition in hypothyroid children. Arch Med Sci. 2010; 6, 3: 407-413;
• Shaarawy M, Fathy SA, Mehany NL, Hindy OW. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure. Clin Chem Lab Med. 2007;45 (11):1498-503
• Shaker OG, El-Shehaby A, Nabih M. Possible role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as markers of plaque instability in coronary artery disease. Angiology. 2010 Nov;61 (8):756-62
• Shargorodsky M, Boaz M, Luckish A, Matas Z, Gavish D, Mashavi M. Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women. Atherosclerosis. 2008 Oct 31;
• Shin MJ, Kim BS, Kim YO, Song HC, Kim Yo, Kim SY, Choi EJ, Chang YS, Bang BK . Association of Arterial Stiffness with the Decrease of Post-Dialysis Blood Pressure in Maintained Hemodialysis Patients. The Korean Journal of Neuphrol. 2008; 27: 102-109;
• Shouman MG, Abdallah NI, Meguid Ak AE, Salama EEE. Bone mineral density markers in children with steroid sensitive idiopathic syndrome. International Journal of Acade. Vol. 2. No. 3. May 2010;
• Skladal P, Jilkova Z, Svoboda I, Kolar V. Investigation of osteoprotegerin interactions with ligands and antibodies using piezoelectric biosensors. Biosens Bioelectron. 2005 Apr 15;20 (10):2027-34
• Stavroulopoulos A, Porter CJ, Pointon K, Monaghan JM, Roe SD, Cassidy MJ. Evolution of coronary artery calcification in patients with chronic kidney disease Stages 3 and 4, with and without diabetes. Nephrol Dial Transplant. 2011 Jan 11;
• Stejskal D, Bartek J, Pastorkova R, Ruzicka V, Oral I, Horalik D. Osteoprotegerin, RANK, RANKL. Biomed Pap Med Fac Univ Palack. 2001 Dec;145 (2):61-4
• Stejskal D, Zurek M, Bartek J, Jedelsky L, Ruzicka V. Osteoprotegerin and bone density. Biomed Pap Med Fac Univ Palack. 2001 Dec;145 (2):75-6
• Sultan A, Avignon A, Galtier F, Piot C, Mariano-Goulart D, Dupuy AM, Cristol JP. Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients. Diabetes Care. 2008 Mar;31 (3):593-5
• Tibullo D, Giallongo C, La Cava P, Berretta S, Stagno F, Chiarenza A, Conticello C, Palumbo GA, Di Raimondo F. Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol. 2009 Apr;37 (4):461-8
• Ulivieri FM, Marchelli D, Como G, Valente G, Messa P, Raimondi AR, Piodi LP. Increased osteoprotegerin in Italian haemodialysis patients. Osteoporos Int. 2006 Dec;17 (12):1822-3; author reply 1824
• Ulivieri FM, Piodi LP, Marotta G, Marchelli D, Corradini C, Parravicini L, Verdoia C, Gerundini P. Usefulness of osteoprotegerin in assessing responses to neridronate treatment in Paget’s disease of bone. J Orthopaed Traumatol 7. 192–194 (2006);
• Vanella L, Kim DH, Asprinio D, Peterson SJ, Barbagallo I, Vanella A, Goldstein D, Ikehara S, Kappas A, Abraham NG. HO-1 expression increases mesenchymal stem cell-derived osteoblasts but decreases adipocyte lineage. Bone. 2010 Jan;46 (1):236-43

References to summary

• Bonnelye E, Aubin JE. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Medscape Womens Health. 2000 Mar;5 (2):5
• Boyle WJ, Lacey DL, Xu W, Tan HL, Scully S, Capparelli C, Tarpley J, Morony S, Dunstan CR, Sarosi I, Bucay N, Simonet WS. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998 May 1;12 (9):1260-8
• Dollerup J, Gormsen LC, Schmitz O, Mogensen CE, Rasmussen LM, Nielsen S, Nellemann B. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care. 2007 Dec;30 (12):3122-4
• Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol. 1999 Sep;141 (3):195-210
• Karan M, Lam A, Mangan S, McCann M, Golledge J. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004 Jul;35 (7):1636-41
• Kerschan-Schindl K, Fureder W, Mitterbauer M, Kudlacek S, Grampp S, Bieglmayer C, Fialka-Moser V, Pietschmann P, Kalhs P. Bone metabolism in patients more than five years after bone marrow transplantation. Bone Marrow Transplant. 2004 Sep;34 (6):491-6
• Lee R, Derby P, Tarpley J, Van G, Sander S, Campbell P, Pattison W, Hill D, Hughes TM, Renshaw-Gegg L, Bucay N, Davy E, Sullivan J, Trail G, Tan HL, Colombero A, Elliott R, DeRose M, Shimamoto G, Boone T, Bennett L, Wooden S, Nguyen HQ, Luthy R, Chang MS, Kelley M, Dunstan CR, Lacey DL, Simonet WS, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 Apr 18;89 (2):309-19
• Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation. 2005 Jun 14;111 (23):3119-25
• Morse LR, Nguyen HP, Jain N, Williams S, Tun CG, Battaglino RA, Stashenko P, Garshick E. Age and motor score predict osteoprotegerin level in chronic spinal cord injury. J Musculoskelet Neuronal Inter. 2008 Jan-Mar;8 (1):50-7
• Ostensen M, Leistad L, Sundan A, Seidel C, Borset M, Feuerherm AJ, Faxvaag A. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol. 2001;30 (4):229-34
• Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C, Capitani S, Zauli G. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol. 2006 Dec;169 (6):2236-44
• Sultan A, Piot C, Mariano-Goulart D, Avignon A, Thuan Dit Dieudonne JF, Cristol JP, Dupuy AM. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007 Nov;30 (11):2934-9
• Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. Eur J Endocrinol. 2001 Dec;145 (6):685-90
• Vilim V, Vytasek R, Olejarova M, Machacek S, Gatterova J, Prochazka B, Kraus VB, Pavelka K. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage. 2001 Oct;9 (7):612-8
• Yamada Y, Higashio K, Ikeda K, Harada A, Goto M, Kobayashi F, Washida N, Tsuda E, Yano K. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res. 1999 Apr;14 (4):518-27

By research topic:

• Bone and cartilage metabolism

By molecule:

• Osteoprotegerin

Registration form